Azora Therapeutics surges 8%

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Azora Therapeutics (AZR.US) surged more than 8% during regular trading to $4.21.

The stock is up 13.21% over the past five sessions, up 170.97% over the past six months and down 23.64% from its IPO price. It sits 221.37% above its 52-week low of US$1.310. The intraday swing reached 10.03%.

The Nasdaq Composite is down 4.13% over the past five sessions and up 9.21% year to date.

Matt Davidson has been appointed president and chief executive officer. The company's lead candidate AT177 for ulcerative colitis is expected to enter a Phase 1 clinical trial in the first half of 2027, and existing cash reserves are projected to fund operations into 2028.

Based on public media reports. AI-generated; not investment advice.

Source: Market Movers The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.